Theo Marchetti

Former asset-management analyst turned writer, focused on making investing legible to people without a finance degree.

Articles by Theo Marchetti

Latest Posts

Gemini Space Station Stock Plunges 13% on Tuesday

Preliminary Results and Executive Exits Trigger Sell-Off Tuesday marked a challenging day for Gemini Space Station (NASDAQ: GEMI), the cryptocurrency

Read

Business

Scandic Hotels Q4 2025 Earnings Presentation Insights

Scandic Hotels Group AB (publ), traded under the ticker OTCMKTS:SCAHF, has recently released its comprehensive slide deck accompanying the fourth

Read

Investing

Baupost’s Seth Klarman Buys Amazon, Sells 41% of Top Rival

Baupost Group’s Value Investor Seth Klarman Increases Stake in Amazon While Reducing Position in Key Competitor On Wall Street, data

Read

Economy

Trump Tariffs to Hit Households with $1,300 Cost in 2026: Stock Impacts

Might the most substantial U.S. tax hike relative to GDP in over three decades influence the stock market? Absolutely, it

Read

Personal Finance

5 Hidden Signs You’re Money-Shy and Blocking Wealth

Living beyond your financial limits and accumulating expensive debt are obvious missteps in money management that most people recognize as

Read

Crypto

Santiment: Crypto Fear Too Low for Bottom Call

Santiment: Crypto Sentiment Lacks Fear for Market Bottom Social media activity reveals that Bitcoin remains in a price zone where

Read

Business

Spark NZ Q2 2026 Earnings Presentation Insights

Spark New Zealand Limited (OTCMKTS: SPKKY) recently released its comprehensive slide deck accompanying the Q2 2026 earnings call, providing investors

Read

Investing

RKLB Stock Soars 111% YTD: SpaceX IPO, Neutron Fuel Rally

Rocket Lab's Sharp Rebound: What's Behind the Recent Momentum Rocket Lab USA, trading under the ticker RKLB on NASDAQ, continues

Read

Investing

Vertex Pharmaceuticals: Resilient Biotech for Any Market Downturn

Vertex Pharmaceuticals possesses the financial strength and revenue potential to thrive regardless of prevailing market conditions. Although Vertex Pharmaceuticals (NASDAQ:

Read